NFBD1, a Novel Nuclear Protein with Signature Motifs of FHA and BRCT, and an Internal 41-Amino Acid Repeat Sequence, Is an Early Participant in DNA Damage Response*

Yong Lei Shang, Amanda J. Bodero, and Phang-Lang ChenDagger

From the Department of Molecular Medicine and Institute of Biotechnology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78245

Received for publication, October 21, 2002, and in revised form, December 3, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Efficient repair of DNA double-strand breaks depends on the intact signaling cascade, comprising molecules involved in DNA damage signal pathways and checkpoints. Budding yeast Rad9 (scRad9) is required for activation of scRad53 (mammalian homolog Chk2) and transduction of the signal further downstream in this pathway. In the search for a mammalian homolog, three proteins in the human data base, including BRCA1, 53BP1, and nuclear factor with BRCT domains protein 1 (NFBD1), were found to share significant homology with the BRCT motifs of scRad9. Because BRCA1 and 53BP1 are involved in DNA damage responses, a similar role for NFBD1 was tested. We show that NFBD1 is a 250-kDa nuclear protein containing a forkhead-associated motif at its N terminus, two BRCT motifs at its C terminus, and 13 internal repetitions of a 41-amino acid sequence. Five minutes after gamma -irradiation, NFBD1 formed nuclear foci that colocalized with the phosphorylated form of H2AX and Chk2, two phosphorylation events known to be involved in early DNA damage response. NFBD1 foci are also detected in response to camptothecin, etoposide, and methylmethanesulfonate treatments. Deletion of the forkhead-associated motif or the internal repeats of NFBD1 has no effect on DNA damage-induced NFBD1 foci formation. Conversely, deletion of the BRCT motifs abrogates damage-induced NFBD1 foci. Ectopic expression of the BRCT motifs reduced damage-induced NFBD1 foci and compromised phosphorylated Chk2- and phosphorylated H2AX-containing foci. These results suggest that NFBD1, like BRCA1 and 53BP1, participates in the early response to DNA damage.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Genomic DNA in all living species is continuously assaulted by exogenous sources, such as environmental mutagens, and endogenous factors, such as reactive oxygen species, that arise during normal cellular metabolism (1). Cells have evolved surveillance mechanisms to promote faithful transmission of genetic information, which involves detection of DNA damage and a resulting signal transduction cascade leading to the induction of cell cycle checkpoints and initiation of DNA repair (2-5). Defects in DNA damage response pathways may result in inefficient repair and accumulation of mutations.

Participants in the DNA damage response pathways can be divided into sensors, proximal kinases, adaptors, transducer kinases, and effectors (4, 5). In budding yeast, a heterotrimeric complex, Rad17-Ddc1-Mec3, which shares homology with proliferating cell nuclear antigen and the replication factor c-like factor Rad24 are thought to be DNA damage sensors (6). Mec1 and Tel1, members of the phosphatidyl inositol-3 kinase-like kinase family, are classified as proximal kinases that activated in response to DNA damage (7, 8). Rad9, an adaptor protein, is phosphorylated by Mec1, which in turn activates the downstream transducer kinase Rad53, a serine/threonine kinase (9-12). Activated Rad53 then further transduces and amplifies signals to downstream effectors that regulate the cell cycle machinery (13-15).

Components of this signaling pathway are conserved in mammals (4, 5). In the initial step of checkpoint activation, DNA damage sensor(s) Rad9-Rad1-Hus1, which share homology with proliferating cell nuclear antigen and the reduced folate carrier protein-like factor Rad17, relay signals to the proximal kinases, ataxia-telangiectasia mutated (ATM)1 and ataxia telangiectasia and Rad3-related (ATR) (16-20). Signals are then amplified by the transducer kinases, Chk1 and Chk2 (21-25). Finally, activation of the downstream effectors, such as p53 and CDC25, leads to cell cycle arrest (26-27).

Budding yeast Rad9 (scRad9) was the first cell cycle checkpoint protein discovered. It is essential for arresting division upon DNA damage (28). When yeast is treated with DNA-damaging agents, scRad9 is phosphorylated, which promotes binding to the C-terminal forkhead homology-associated (FHA) motif of Rad53 (12). Therefore, scRad9 plays a critical role in this signaling pathway by ensuring that the damage signal is transduced downstream. A mammalian homologue of scRad9, however, has not been identified. The structural signature motifs of scRad9 are two BRCT repeats in its C terminus. Based on this structural similarity, it was predicted that three mammalian proteins, BRCA1, p53BP1, and an uncharacterized protein, KIAA0170, might be the candidates for the scRad9 homologue (29-31). Only BRCA1 and 53BP1 have been significantly characterized to date.

In addition to their structural similarity, BRCA1 and Rad9 both serve as substrates of ATM and ATR kinases in response to DNA damage (32-34) and compromised G2/M checkpoint control upon inactivation (35). However, BRCA1 also has unique functions, including acting as a substrate of Chk2 (36), directly participating in homologous recombination, and microhomology-mediated end-joining through interaction with the Rad50-Mre11-NBS1 complex (37-39). Moreover, BRCA1 contains a ring-finger motif at its N terminus and has ubiquitin ligase activity (40). BRCA1 also interacts with many transcription factors and coordinately regulates the critical cell cycle inhibitor p21 and the G2/M checkpoint protein Gadd45 (41). Because of these diverse functions, BRCA1 may not be a bona fide homolog of Rad9. Another protein, 53BP1 also resembles scRad9. It has two C-terminal BRCT repeats and participates in early DNA damage response (42-43). It is also a substrate for ATM (44-45) and is required for G2/M checkpoint arrest in response to gamma -irradiation (46). Thus, 53BP1 seems to be even more functionally similar to scRad9 than BRCA1.

KIAA0170 was an anonymous gene identified by random sequencing of cDNA library derived from a human immature myeloid cell line (47). The KIAA0170 gene product was later reported to have transactivation activity and was renamed `nuclear factor contains BRCT domains protein 1' (NFBD1) (48). NFBD1 is predicted to have an N-terminal FHA motif (49) and two C-terminal BRCT repeats. Besides this preliminary characterization of secondary structure, however, very little is known about NFBD1. In particular, nothing has yet been published about its potential function in the DNA damage response. Here, we show for the first time that NFBD1 does participate in the early DNA damage responses. Deletion of BRCT motifs, but not the FHA motif or the internal repeats of NFBD1, abolished foci formation. Ectopic expression of the NFBD1-derived BRCT motifs greatly reduced IR-induced nuclear foci containing NFBD1, Chk2 phosphorylated at threonine 68 (Chk2T68P), and H2AX phosphorylated on serine 139 (gamma -H2AX).

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Construction of Plasmids-- The NFBD1 full-length cDNA (kindly provided by T. Nagase, Kazusa DNA Research Institute, Chiba, Japan) was cloned into the EGFP-C2 expression vector (Clontech, Palo Alto, CA). Subsequent motif deletions were made in the EGFP-NFBD1 construct using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by DNA sequencing. Primers encoding the nuclear localization signal were synthesized, annealed, and cloned into EGFP-C2. The fragment containing the BRCT motifs of NFBD1 (codon 1839-2089) was obtained by polymerase chain reaction using Pfu polymerase (Stratagene) and cloned in-frame with nuclear localization signal in EGFP-C2.

Cell Culture and Treatments with DNA-damaging Agents-- HeLa, a human cervical carcinoma cell line; IMR90, a human diploid fibroblast; and LEM, an Epstein-Barr virus-immortalized human B cell line, were cultured in Dulbeco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 units of penicillin, and 50 µg/ml of streptomycin at 37 °C with 10% CO2. Cells grown in log-phase were irradiated in a 137Cs radiation source (Mark I, Model 68A Irradiator; JL Shepherd & Associates). UV irradiation was performed using a Stratalinker UV source (Stratagene). Before UV irradiation, the culture medium was removed and cells were washed once with phosphate-buffered saline. The medium was replaced immediately after irradiation. All the cells were then cultured at 37 °C and harvested at the indicated time points. For treatment with genotoxic agents, the cells were exposed for 1 h at the indicated dose, washed with phosphate-buffered saline, and cultured in fresh medium for another hour before being fixed for immunostaining. Untreated or mock-treated cells were treated identically with phosphate-buffered saline washes and medium changes but no irradiation.

Antibodies-- The fragment of the NFBD1 gene encoding amino acids 2-224 was amplified by polymerase chain reaction using Pfu polymerase (Stratagene) and was cloned into the pGEX vector (Amersham Biosciences). The recombinant protein was expressed in BL21-LysS cells and purified with glutathione S-transferase beads. The purified recombinant protein was resolved by SDS-polyacrylamide gel electrophoresis and stained with imidazole-zinc. The polypeptide band was excised, electroeluted from the gel, and subsequently used as an antigen to immunize mice and rabbits. Rabbit antibodies were purified using antigen-coupled affinity chromatography. Rabbit alpha -gamma -H2AX was purchased from Upstate Biotechnology (Lake Placid, NY), rabbit alpha -Chk2T68P from Cell Signaling Technology (Beverly, MA), and mouse alpha -GFP from Roche Applied Science.

Immunoprecipitations and Western Blotting-- [35S]Methionine labeling, immunoprecipitations, and immunoblotting were performed as described previously (50, 51). alpha -NFBD1 and alpha -GFP monoclonal antibodies were used for antigen detection in the immunoblots.

Immunostaining-- Procedures for immunostaining were adapted from Durfee et al. (52). Briefly, cells grown on coverslips to 60-70% confluence were treated with various DNA-damaging agents and fixed in 3% formaldehyde with 0.1% Triton X-100. Cells on coverslips were permeabilized by 0.05% saponin and blocked with 10% normal goat serum. All primary antibodies were used at a dilution of 1:100 to 1:1000 in 10% goat serum. The secondary antibodies, including anti-rabbit or mouse Alexa 555 and anti-rabbit or anti-mouse Alexa 488 (Molecular Probes, Eugene, OR) were used at a dilution of 1:1000. Cells were further stained with 4',6-diamidino-2-phenylindole for detection of DNA and mounted in Permafluor (Lipshaw-Immunonon, Pittsburgh, PA). Immunofluorescence images were captured using a Zeiss Axiplan2 fluorescence microscope.

Transfections-- Transfections were performed using Lipofectin (Invitrogen) according to the manufacturer's instructions. The transfected cells were supplemented with fresh medium and irradiated at 36-38 h after transfection.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Identification of Cellular NFBD1 Protein with Anti-NFBD1 Antibodies-- We found that NFBD1, in addition to its N-terminal FHA motif and two C-terminal BRCT motifs, had 13 unique internal repeats, each containing 41 amino acids enriched with serine, threonine, and proline residues (Fig. 1). Interestingly, potential ATM/ATR and cyclin-dependent kinase phosphorylation sites are scattered throughout these repeats. To identify the encoded protein of NFBD1, we used the recombinant GST fusion protein containing the N-terminal 223 amino acids of NFBD1 as an antigen (named GST-FHA) to raise mouse and rabbit polyclonal antibodies. Cell extracts prepared from [35S]methionine-labeled lymphoid cells (LEM) were used for immunoprecipitation with either mouse NFBD1 antisera or preimmune serum. As shown in Fig. 1C, a protein with an apparent molecular mass of 250 kDa, which is near the predicted molecular mass, was specifically immunoprecipitated by anti-NFBD1 antisera but not pre-immune sera (lanes 1 and 2). Addition of the original GST-FHA antigen (lane 4), but not GST alone (lane 3), blocked the immunoprecipitation of 250-kDa protein. To further ensure the specificity of the antibodies, the anti-NFBD1 immunoprecipitates were released and reprecipitated by anti-NFBD1, as described previously (51). Under these conditions, only the single 250-kDa band was detected (lane 5), suggesting that the NFBD1 antisera were specific for the 250-kDa protein. In addition, protein with the same relative mobility was also immunoprecipitated by rabbit NFBD1 antisera (lane 6). Mouse (lane 7) and rabbit (lane 8) NFBD1 antibodies specifically purified by antigen-coupled affinity chromatography also detected a major band with the same apparent mobility, although minor bands with faster mobilities were also detected. The latter may be degradation products of NFBD1 or yet to be identified proteins. These results suggest that a protein with an apparent mass of ~250 kDa is the endogenous NFBD1 gene product.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 1.   Protein structure of NFBD1 and characterization of anti-NFBD1 antibodies. A, human NFBD1 protein has a single FHA motif, 13 internal repeats, and two BRCT motifs. B, alignment of 13 internal repeats shows high homology of the 41 amino acid repeats. C, [35S]methionine-labeled cell extracts were used for immunoprecipitation (IP) in the presence of mouse anti-NFBD1 serum (lane 2), serum preincubated with GST protein (lane 3), or serum preincubated with GST protein fused antigen (lane 4). Pre-immune serum was used as a negative control (lane 1). To remove nonspecific binding, the immunoprecipitation products were dissociated and immunoprecipitated a second time with mouse anti-NFBD1 serum (lane 5). Rabbit NFBD1 anti-serum was also used for immunoprecipitation (lane 6). Affinity-purified mouse (lane 7) and rabbit (lane 8) anti-NFBD1 were used for immunoblotting.

NFBD1 Forms Nuclear Foci upon Treatment with Various DNA-damaging Agents-- Proteins involved in DNA damage response pathway, including 53BP1 and BRCA1, form subnuclear foci after DNA damage (42, 43, 53). To determine whether NFBD1 has similar properties, we examined its subcellular localization by immunostaining with anti-NFBD1 antibodies. In actively growing HeLa cells, purified rabbit NFBD1 antisera but neither pre-immune nor GST-FHA antigen block demonstrated immunoreactivity confined to nuclei (Fig. 2A). HeLa cells treated with ionizing radiation (IR) showed distinct nuclear foci positive for anti-NFBD1 immunoreactivity (Fig. 2B). To confirm that these signals are attributed to NFBD1, full-length NFBD1 protein was tagged with GFP and expressed in the same HeLa cells. GFP-NFBD1, like endogenous NFBD1, localized exclusively in nuclei and was present in subnuclear foci after IR (Fig. 2C). Furthermore, when HeLa cells expressing the GFP-NFBD1 were immunostained with anti-NFBD1 antibodies, the IR-induced nuclear foci derived from GFP signals (exogenous) colocalized with the foci detected by immunostaining with anti-NFBD1 antibodies (endogenous) (Fig. 3D). These results suggest that NFBD1 is present in nuclear foci upon IR.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   NFBD1 forms nuclear foci in response to IR. A, actively growing HeLa cells were fixed and stained with preimmune serum, purified rabbit anti-NFBD1, anti-NFBD1 in the presence of GST protein, or GST-fused antigen (GST-FHA) respectively. B, HeLa cells irradiated (Gy) were stained with preimmune serum, purified rabbit anti-NFBD1, anti-NFBD1 in the presence of GST protein, or GST-fused antigen (GST-FHA) for different panels. NFBD1, NFBD1 immunofluorescence; DAPI, 4',6-diamidino-2-phenylindole staining of cell nuclei. C, relocalization of EGFP-tagged NFBD1 in transiently transfected cells in response to IR (Gy), EGFP alone as a negative control. D, transiently transfected GFP-tagged NFBD1 (exogenous) in HeLa cells colocalizes with NFBD1 (anti-NFBD1) after IR (Gy). Yellow dots indicate the colocalization.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   NFBD1 relocalizes to nuclear foci in response to treatments with various DNA damaging-agents. HeLa cells were treated with gamma -radiation (Gy and Gy) or UV (50 J/m2). Cells were fixed and immunostained for NFBD1 after 30 min. Cells were also treated with 0.5 µg/ml mitomycin C (MMC), 2 µM camptothecin (CPT), 40 µg/ml etoposide (VP16), or 0.01% methylmethanesulfonate (MMS) for 1 h, washed, and refed with fresh medium (without drugs) and incubated for another hour, then fixed and immunostained with rabbit anti-NFBD1.

Next we tried to determined whether the foci that form in response to other DNA-damaging agents contain NFBD1. Camptothecin, a DNA topoisomerase I inhibitor, and etoposide, a topoisomerase II inhibitor, produced single-strand breaks and double-strand breaks (DSBs), respectively. Treatment with these two drugs induced prominent formation of foci containing NFBD1. Similar results were also observed in cells treated with the alkylating agent methylmethanesulfonate or the cross-linking agent mitomycin C, which both produce synthetic strand breaks (Fig. 3). Cells treated with UV light, which causes pyrimidine dimers but not DSBs, showed only a few foci positive for NFBD1 (Fig. 3). These results suggest damage-specific recruitment of NFBD1 to subnuclear foci during cellular responses.

NFBD1 Forms Foci Very Early in Response to IR-- DNA DSBs induce formation of nuclear foci at the sites of breaks containing several damage response proteins. First, we characterized the kinetics of NFBD1 foci formation induced by IR in a normal human fibroblast line, IMR90. Cells were fixed at different time points after 1 Gy of gamma -irradiation and immunostained with NFBD1 antisera. NFBD1-containing foci were clearly present within 5 min after IR (Fig. 4A). The average number of NFBD1-positive foci per cell increased with time and peaked 30 min after irradiation. Gradually, the number of NFBD1-positive foci decreased to background levels within 4 h (Fig. 4B). The percentage of cells with more than five NFBD1 foci in the entire culture populations were also counted. The percentage of cells with IR-induced foci reached a peak of 95% within 5 min after IR, then gradually decreased to the background level after 4 h (Fig. 4B). These results indicate that cells, regardless of cell cycle stage, responded to form IR-induced foci containing NFBD1. They further suggest that NFBD1 localizes at sites of DNA breaks and participates in the early DNA damage response.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   The kinetics of NFBD1 focus formation in response to gamma -radiation. A, immunofluorescence of IMR90 human fibroblast cells exposed to 1 Gy of radiation was examined for NFBD1 foci at the indicated time points. B, the average number of foci per cell was plotted versus time () and the percentage of cells with more than five foci was plotted versus time (open circle ). 50 cells were counted per data point.

Colocalization of NFBD1, gamma -H2AX, and Phosphorylated Chk2 at IR-induced Foci-- gamma -H2AX and Chk2T68P form nuclear foci at the sites of DNA DSBs upon IR (54, 55). H2AX is a variant of H2A that undergoes phosphorylation at serine 139. gamma -H2AX appears in discrete nuclear foci at sites of DNA breaks within 1-3 min after irradiation. The kinetics of NFBD1-positive foci formation described above are similar to those of gamma -H2AX (54, 56), prompting us to ask whether NFBD1 and co-localize in IR-induced foci. Indeed, NFBD1 and gamma -H2AX immunoreactivity colocalize in foci that formed within 15 min to 4 h after irradiation (Fig. 5A).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 5.   Colocalization of NFBD1 with gamma -H2AX and Chk2T68P in response to gamma -radiation. A, HeLa cells untreated or treated with gamma -radiation (8 Gy) were fixed 30 min after irradiation and costained with anti-NFBD1 (red) and anti-gamma -H2AX antibody (green). B, after mock treatment or gamma -radiation (8 Gy), cells were fixed and co-stained with anti-NFBD1 (red) and anti-Chk2T68P (green). Yellow dots indicate colocalization.

In addition to gamma -H2AX, Chk2, a mammalian homologue of the transducing kinase Rad53, was also examined. In response to IR, ATM rapidly phosphorylates Chk2 at threonine 68, which activates Chk2 kinase activity (23, 57, 58) and its relocation to sites of DNA DSBs (55). To test whether NFBD1 also co-localizes with Chk2T68P after IR, we immunostained irradiated cells using antibodies specific for T68-phosphorylated Chk2. As shown in Fig. 5B, immunoreactivity to both Chk2T68P and NFBD1 antibodies colocalized at the IR-induced foci at all time points from 15 min to 4 h after irradiation. Collectively, these results indicate that NFBD1, like gamma -H2AX and Chk2T68P, is recruited to sites of DNA breaks during the early stage of the response to DNA damage.

Localization of NFBD1 at IR-induced Foci Requires BRCT Motifs-- NFBD1 contains three significant signature motifs. Each of them can be important in mediating the function it plays in DNA damage response. To determine which of the three motifs of NFBD1 was essential for the IR-induced foci formation, we generated deletion mutants of NFBD1 that removed them individually (Fig. 6A). The mutated proteins were N-terminally tagged with GFP, and their expression was assayed in transfected HeLa cells by immunoprecipitation with anti-GFP antibodies followed by Western blotting. As shown in Fig. 6B, each of the mutated proteins was detected in transfected HeLa cells. Interestingly, all the mutated fusion proteins were localized in nuclei, suggesting that none are important for nuclear localization of NFBD1 (Fig. 6C). Removal of the C-terminal BRCT motifs, but not the N-terminal FHA motif or the internal repeats, abolished its localization in IR-induced foci (Fig. 6C). These results indicate that the BRCT motif is essential for the localization of NFBD1 to IR-induced foci.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 6.   BRCT motifs are required for NFBD1 focus formation in response to IR. A, schematic diagram of wild-type GFP-NFBD1 and deletion mutants. Boxes indicate the remaining region of NFBD1. B, protein expression for wild-type GFP-NFBD1 and GFP-NFBD1 mutants. Cell extracts prepared from HeLa cells transfected with either wild-type or mutant NFBD1 plasmid constructs were used for IP with anti-GFP (Roche Applied Science), and then immunoblotted using anti-GFP. C, GFP vectors carrying wild-type or different mutants were transiently transfected into HeLa cells. 24 h later, cells were left untreated or treated with gamma -radiation (8 Gy) and fixed 30 min after mock treatment or irradiation. Fixed cells were directly observed using fluorescent microscopy.

Expression of the BRCT Motif of NFBD1 Abolishes IR-induced Foci Formation-- The major function of the BRCT motifs is to establish protein-protein interactions. Their limited sequence homology indicates that each BRCT motif has a distinct binding partner. To determine the effect of expression of the BRCT motifs in NFDB1 on NFBD1 subnuclear partitioning, we generated a plasmid to express a GFP-BRCT fusion protein that also contains a nuclear localization signal. Cells transfected and expressing GFP-BRCT, but not GFP alone, demonstrated significantly reduced NFBD1 immunoreactive foci (Fig. 7A), suggesting that the BRCT motifs have a dominant-negative effect on NFBD1 localization.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 7.   Overexpression of the BRCT motifs of NFBD1 disrupts formation of foci containing NFBD1, gamma -H2AX, and Chk2T68P in response to IR. Vectors containing EGFP alone or the BRCT motifs fused with EGFP were transiently transfected into HeLa cells. 30 min after gamma -radiation (Gy), cells were fixed and stained for NFBD1 (A and B), gamma -H2AX (C and D), or Chk2T68P (E and F). GFP (green fluorescence) signal indicates the transfected cells.

Because NFBD1 colocalizes with gamma -H2AX and Chk2T68P at IR-induced foci upon irradiation, we tested whether gamma -H2AX- and Chk2T68P-containing foci would be altered in cells expressing the NFBD1-derived GFP-BRCT fusion protein. We immunostained the transfected cells with anti-gamma -H2AX and found that the intensity of gamma -H2AX staining was similar to that of the control, indicating that the phosphorylation of H2AX remained intact (Fig. 7, C and D). IR-induced foci were substantially reduced, however, in cells expressing the dominant-negative GFP-BRCT fusion protein (Fig. 7D). These results suggest that NFBD1 may have a role in recruitment of gamma -H2AX to sites of DNA breaks but no obvious role in H2AX phosphorylation at serine 139. Similarly, when we immunostained the transfected cells with anti- Chk2T68P antibodies, IR-induced Chk2T68P foci were diminished in the presence of GFP-BRCT (Fig. 7F), suggesting that NFBD1 is also required for recruitment of Chk2T68P to sites of DNA breaks.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In a search for a mammalian homolog of scRad9, a critical adaptor protein in DNA damage signal pathway, we characterized a novel nuclear protein, NFBD1, the BRCT motifs of which share significant homology with those of scRad9. NFBD1 was identified as a 250-kDa nuclear protein with specific antibodies. Within 5 min after IR, NFBD1 was found in nuclear foci, which also seemed to contain phosphorylated forms of H2AX (gamma -H2AX) and Chk2 (Chk2T68P), two proteins known to be involved in early DNA damage response. NFBD1 foci formation was also detected in response to camptothecin, etoposide, and methylmethanesulfonate treatment. Deletion of the BRCT motif of NFBD1 had significant effects on the formation of IR-induced foci containing NFBD1. Moreover, ectopic expression of the NFBD1-derived BRCT motif alone not only greatly reduced IR-induced formation of foci containing NFBD1 but also reduced formation of foci containing either Chk2T68P or gamma -H2AX. These results suggest that NFBD1 participates in the early stage of cellular response to DNA damage, a functional property similar to that of scRad9.

In the DNA damage signal cascade of budding yeast, Rad9 is required for the activation of the Chk2 homolog Rad53 (10). Phosphorylation of Rad9 by Mec1 upon DNA damage results in the formation of an epitope that binds to the FHA motif of Rad53. Rad9 self-associates (59) and forms oligomers to bring two Rad53 molecules into close proximity to facilitate in trans autophosphorylation of the bound Rad53 molecules (60). Thus, Rad9 serves as an adaptor to recruit Rad53.

In mammalian cells, Chk2 activation in response to IR requires initial phosphorylation of Thr-68 by ATM and subsequent autophosphorylation (57, 58, 61). How Thr-68 phosphorylation leads to Chk2 autophosphorylation and activation is currently unclear. Because the DNA damage signaling pathway is highly conserved among different eukaryotes and because ATM can only phosphorylate Chk2 but fails to activate it in vitro (58), it is likely that an adaptor protein for Chk2 activation exists in mammals. 53BP1 and BRCA1 were speculated as the adaptors for Chk2 activation, but in the absence of functional BRCA1, Chk2 nonetheless can be efficiently activated upon IR. On the other hand, depletion of 53BP1 can partially affect the phosphorylation of Chk2 at T68 (46). Thus, 53BP1, but not BRCA1, may serve as an adaptor protein to facilitate Chk2 activation. Our immunostaining results have shown that NFBD1 colocalizes with Chk2T68P at the site of DNA breaks, and overexpression of the NFBD1-derived BRCT motif diminished the IR-induced foci positive for Chk2T68P. This finding, combined with structural clues, suggests an intriguing possibility that NFBD1 may also function as an adaptor protein, and is required for the phosphorylation of Chk2 and its localization to DNA break sites. However, further biochemical and genetic evidence is required to directly support this possibility.

A known function of BRCT motifs is to enable protein-protein interaction, and many proteins in the DNA damage response pathways contain them (30, 31). However, the sequence homology among BRCT motifs is limited, although they form a similar three-dimensional structure (62-65). We have shown that the BRCT motif of NFBD1 is required for its localization to the site of DNA breaks and that overexpression of this specific motif abolished IR-induced foci containing NFBD1 and Chk2T68P. These results suggest that the BRCT motif of NFBD1 has a dominant-negative effect on NFBD1 function. This notion is consistent with the potential role of NFBD1 as an adaptor protein.

Several examples of protein-protein interactions important for DNA damage responses are known. Interaction between BRCA1 and CtIP is mediated by BRCT motifs (66-68) and has been shown to play an important role in regulating Gadd45, a critical G2/M checkpoint protein (69). In addition, the BRCT motifs of 53BP1 interact with p53 (64, 65, 70), a key player in both G1/S and G2/M checkpoint response, as well as in DNA damage-induced apoptosis (71). However, our preliminary results show that the expression of the BRCT motif of BRCA1 or 53BP1 has no influence on NFBD1 foci formation (data not shown), suggesting that the BRCT motif of NFBD1 has a unique role independent of BRCA1 or 53BP1 in the DNA damage response signaling pathway.

Phosphorylation of histone H2AX on serine 139 by ATM has been observed in response to DNA double-strand breaks (72) and by ATR in response to DNA replicative stress (73). gamma -H2AX is found in subnuclear foci, which colocalize with BRCA1 and 53BP1 at the arrested replication fork in S-phase cells (43, 65). In the absence of histone H2AX, cells display increased sensitivity to ionizing radiation and increased genomic instability (74). These observations suggest a critical role for H2AX in the mammalian DNA damage response. The effects of NFBD1-derived BRCT motifs we observed on the IR-induced foci formation of gamma -H2AX suggest that functional NFBD1 may play a role in the recruitment of gamma -H2AX to sites of DNA breaks but very little role in the phosphorylation of H2AX at serine 139. Although further confirmation is needed, our data suggest that NFBD1 may play little role in sensing DNA damage.

The results presented in this study suggest strongly that NFBD1 may serve as an adaptor protein in the DNA damage response pathway in mammalian cells. Because mutation of either BRCA1 (75) or Chk2 accounts for some hereditary cases of breast cancer (76), mutation of NFBD1 may also be a potential contributing factor to the formation of breast or other cancers. Further elucidation of the precise role(s) that NFBD1 plays in DNA damage response and in tumor formation will address this intriguing possibility.

    ACKNOWLEDGEMENTS

We are grateful to Dr. Takahiro Nagase at Kazusa DNA Research Institute for providing NFBD1 (KIAA0170) cDNA. We thank Paula Garza and Diane Jones for antibody preparation, Guikai Wu and Aimin Peng for helpful discussion, Nicholas Ting, Dave Sharp, and Daniel Riley for critically reading the manuscript, and Wen-Hwa Lee for his encouragement and support.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant CA85605 (to P.-L. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Molecular Medicine and Institute of Biotechnology, The University of Texas Health Science Center at San Antonio, 15355 Lambda Dr., San Antonio, TX 78245. Tel.: 210-567-7353; Fax: 210-567-7377; E-mail: chenp0@uthscsa.edu.

Published, JBC Papers in Press, December 9, 2002, DOI 10.1074/jbc.M210749200

    ABBREVIATIONS

The abbreviations used are: ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related; FHA, forkhead-associated; NFBD1, nuclear factor with BRCT domains protein 1; EGFP, enhanced green fluorescent protein; Chk2T68P, Chk2 phosphorylated at threonine 68; gamma -H2AX, H2AX phosphorylated at serine 139; GFP, green fluorescence protein; GST, glutathione S-transferase; IR, ionizing radiation; DSB, double-strand break; Gy, gray; 53BP1, tumor suppressor p53-binding protein 1.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Hartwell, L. (1992) Cell 71, 543-546[Medline] [Order article via Infotrieve]
2. Nurse, P. (1997) Cell 91, 865-867[Medline] [Order article via Infotrieve]
3. Melo, J., and Toczyski, D. (2002) Curr. Opin. Cell Biol. 14, 237-245[CrossRef][Medline] [Order article via Infotrieve]
4. Rouse, J., and Jackson, S. P. (2002) Science 297, 537-551[Abstract/Free Full Text]
5. Zhou, B. B., and Elledge, S. J. (2002) Nature 408, 433-439[CrossRef]
6. Melo, J. A., Cohen, J., and Toczyski, D. P. (2001) Genes Dev. 15, 2809-2821[Abstract/Free Full Text]
7. Morrow, D. M., Tagle, D. A., Shiloh, Y., Collins, F. S., and Hieter, P. (1995) Cell 82, 831-840[Medline] [Order article via Infotrieve]
8. Jackson, S. P. (1996) Curr. Opin. Genet. Dev. 6, 19-25[Medline] [Order article via Infotrieve]
9. Sun, Z., Hsiao, J., Fay, D. S., and Stern, D. F. (1998) Science 281, 272-274[Abstract/Free Full Text]
10. Vialard, J. E., Gilbert, C. S., Green, C. M., and Lowndes, N. F. (1998) EMBO J. 17, 5679-5688[Abstract/Free Full Text]
11. Emili, A. (1998) Mol. Cell 2, 183-189[Medline] [Order article via Infotrieve]
12. Schwartz, M. F., Duong, J. K., Sun, Z., Morrow, J. S., Pradhan, D., and Stern, D. F. (2002) Mol. Cell 9, 1055-1065[Medline] [Order article via Infotrieve]
13. Pellicioli, A., Lucca, C., Liberi, G., Marini, F., Lopes, M., Plevani, P., Romano, A., Di, Fiore, P. P., and Foiani, M. (1999) EMBO J. 18, 6561-6572[Abstract/Free Full Text]
14. Schramke, V., Neecke, H., Brevet, V., Corda, Y., Lucchini, G., Longhese, M. P., Gilson, E., and Geli, V. (2001) Genes Dev. 15, 1845-1858[Abstract/Free Full Text]
15. Zhao, X., Chabes, A., Domkin, V., Thelander, L., and Rothstein, R. (2001) EMBO J. 20, 3544-3553[Abstract/Free Full Text]
16. Rauen, M., Burtelow, M. A., Dufault, V. M., and Karnitz, L. M. (2000) J. Biol. Chem. 275, 29767-29771[Abstract/Free Full Text]
17. Venclovas, C., and Thelen, M. P. (2000) Nucleic Acids Res. 28, 2481-2493[Abstract/Free Full Text]
18. Post, S., Weng, Y. C., Cimprich, K., Chen, L. B., Xu, Y., and Lee, E. Y. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13102-13107[Abstract/Free Full Text]
19. Bao, S., Tibbetts, R. S., Brumbaugh, K. M., Fang, Y., Richardson, D. A., Ali, A., Chen, S. M., Abraham, R. T., and Wang, X. F. (2001) Nature 411, 969-974[CrossRef][Medline] [Order article via Infotrieve]
20. Zou, L., Cortez, D., and Elledge, S. J. (2002) Genes Dev. 15, 198-208[CrossRef]
21. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997) Science 277, 1497-1501[Abstract/Free Full Text]
22. Brown, A. L., Lee, C. H., Schwarz, J. K., Mitiku, N., Piwnica-Worms, H., and Chung, J. H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3745-3750[Abstract/Free Full Text]
23. Matsuoka, S., Huang, M., and Elledge, S. J. (1998) Science 282, 1893-1897[Abstract/Free Full Text]
24. Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., Donehower, L. A., and Elledge, S. J. (2000) Genes Dev. 14, 1448-1459[Abstract/Free Full Text]
25. Zhao, H., and Piwnica-Worms, H. (2001) Mol. Cell. Biol. 21, 4129-4139[Abstract/Free Full Text]
26. Bartek, J., and Lukas, J. (2001) Curr. Opin. Cell Biol. 13, 738-747[CrossRef][Medline] [Order article via Infotrieve]
27. Taylor, W. R., and Stark, G. R. (2001) Oncogene 20, 1803-1815[CrossRef][Medline] [Order article via Infotrieve]
28. Weinert, T. A., and Hartwell, L. H. (1988) Science 241, 317-322[Medline] [Order article via Infotrieve]
29. Koonin, E. V., Altschul, S. F., and Bork, P. (1996) Nat. Genet. 13, 266-268[Medline] [Order article via Infotrieve]
30. Bork, P., Hofmann, K., Bucher, P., Neuwald, A. F., Altschul, S. F., and Koonin, E. V. (1997) FASEB J. 11, 68-76[Abstract/Free Full Text]
31. Callebaut, I., and Mornon, J. P. (1997) FEBS Lett. 400, 25-30[CrossRef][Medline] [Order article via Infotrieve]
32. Cortez, D., Wang, Y., Qin, J., and Elledge, S. J. (1999) Science 286, 1162-1166[Abstract/Free Full Text]
33. Tibbetts, R. S., Cortez, D., Brumbaugh, K. M., Scully, R., Livingston, D., Elledge, S. J., and Abraham, R. T. (2000) Genes Dev. 14, 2989-3002[Abstract/Free Full Text]
34. Xu, B., Kim, S. t., and Kastan, M. B. (2001) Mol. Cell. Biol. 21, 3445-3450[Abstract/Free Full Text]
35. Xu, X., Weaver, Z., Linke, S. P., Li, C., Gotay, J., Wang, X. W., Harris, C. C., Ried, T., and Deng, C. X. (1999) Mol. Cell 3, 389-395[Medline] [Order article via Infotrieve]
36. Lee, J. S., Collins, K. M., Brown, A. L., Lee, C. H., and Chung, J. H. (2000) Nature 404, 201-204[CrossRef][Medline] [Order article via Infotrieve]
37. Moynahan, M. E., Chiu, J. W., Koller, B. H., and Jasin, M. (1999) Mol. Cell 4, 511-518[Medline] [Order article via Infotrieve]
38. Zhong, Q., Chen, C. F., Chen, P. L., and Lee, W. H. (2002) J. Biol. Chem. 277, 28641-28647[Abstract/Free Full Text]
39. Zhong, Q., Boyer, T. G., Chen, P. L., and Lee, W. H. (2002) Cancer Res. 62, 3966-3970[Abstract/Free Full Text]
40. Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., and Ohta, T. (2001) J. Biol. Chem. 276, 14537-14540[Abstract/Free Full Text]
41. Zheng, L., Li, S., Boyer, T. G., and Lee, W. H. (2000) Oncogene 19, 6159-6175[CrossRef][Medline] [Order article via Infotrieve]
42. Schultz, L. B., Chehab, N. H., Malikzay, A., and Halazonetis, T. D. (2000) J. Cell Biol. 151, 1381-1390[Abstract/Free Full Text]
43. Rappold, I., Iwabuchi, K., Date, T., and Chen, J. (2001) J. Cell Biol. 153, 613-620[Abstract/Free Full Text]
44. Xia, Z., Morales, J. C., Dunphy, W. G., and Carpenter, P. B. (2001) J. Biol. Chem. 276, 2708-2718[Abstract/Free Full Text]
45. Anderson, L., Henderson, C., and Adachi, Y. (2001) Mol. Cell. Biol. 21, 1719-1729[Abstract/Free Full Text]
46. Wang, B., Matsuoka, S., Carpenter, P. B., and Elledge, S. J. (2002) Science (epub ahead of print)
47. Nagase, T., Seki, N., Ishikawa, K., Tanaka, A., and Nomura, N. (1996) DNA Res 3, 17-24[Medline] [Order article via Infotrieve]
48. Ozaki, T., Nagase, T., Ichimiya, S., Seki, N., Ohiri, M., Nomura, N., Takada, N., Sakiyama, S., Weber, B. L., and Nakagawara, A. (2000) DNA Cell Biol. 19, 475-485[CrossRef][Medline] [Order article via Infotrieve]
49. Hofmann, K., and Bucher, P. (1995) Trends Biochem. Sci 20, 347-349[CrossRef][Medline] [Order article via Infotrieve]
50. Chen, P. L., Scully, P., Shew, J. Y., Wang, J. Y., and Lee, W. H. (1989) Cell 58, 1193-1198[Medline] [Order article via Infotrieve]
51. Chen, Y., Farmer, A. A., Chen, C.-F., Jones, D. C., Chen, P.-L., and Lee, W.-H. (1996) Cancer Res. 56, 3168-3172[Abstract]
52. Durfee, T., Mancini, M. A., Jones, D., Elledge, S. J., and Lee, W.-H. (1994) J. Cell Biol. 127, 609-622[Abstract]
53. Zhong, Q., Chen, C. F., Li, S., Chen, Y., Wang, C. C., Xiao, J., Chen, P. L., Sharp, Z. D., and Lee, W. H. (1999) Science 285, 747-750[Abstract/Free Full Text]
54. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., and Bonner, W. M. (1998) J. Biol. Chem. 273, 5858-5868[Abstract/Free Full Text]
55. Ward, I. M., Wu, X., and Chen, J. (2001) J. Biol. Chem. 276, 47755-47758[Abstract/Free Full Text]
56. Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., and Bonner, W. M. (2000) Curr. Biol. 10, 886-895[CrossRef][Medline] [Order article via Infotrieve]
57. Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H., and Canman, C. E. (2000) Cancer Res. 60, 5934-5936[Abstract/Free Full Text]
58. Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., and Elledge, S. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10389-10394[Abstract/Free Full Text]
59. Soulier, J. (1999) Curr. Biol. 9, 551-554[CrossRef][Medline] [Order article via Infotrieve]
60. Gilbert, C. S., Green, C. M., and Lowndes, N. F. (2001) Mol. Cell 8, 129-136[Medline] [Order article via Infotrieve]
61. Melchionna, R., Chen, X. B., Blasina, A., and McGowan, C. H. (2000) Nat. Cell. Biol. 2, 762-765[CrossRef][Medline] [Order article via Infotrieve]
62. Zhang, X., Morera, S., Bates, P. A., Whitehead, P. C., Coffer, A. I., Hainbucher, K., Nash, R. A., Sternberg, M. J., Lindahl, T., and Freemont, P. S. (1998) EMBO J. 17, 6404-6411[Abstract/Free Full Text]
63. Williams, R. S., Green, R., and Glover, J. N. (2001) Nat. Struct. Biol. 8, 838-842[CrossRef][Medline] [Order article via Infotrieve]
64. Joo, W. S., Jeffrey, P. D., Cantor, S. B., Finnin, M. S., Livingston, D. M., and Pavletich, N. P. (2002) Genes Dev. 16, 583-593[Abstract/Free Full Text]
65. Derbyshire, D. J., Basu, B. P., Serpell, L. C., Joo, W. S., Date, T., Iwabuchi, K., and Doherty, A. J. (2002) EMBO J. 21, 3863-3872[Abstract/Free Full Text]
66. Wong, A. K., Ormonde, P. A., Pero, R., Chen, Y., Lian, L., Salada, G., and Berry, S. (1998) Oncogene 17, 2279-2285[CrossRef][Medline] [Order article via Infotrieve]
67. Yu, X., Wu, L. C., Bowcock, A. M., Aronheim, A., and Baer, R. (1998) J. Biol. Chem. 273, 25388-25392[Abstract/Free Full Text]
68. Li, S., Chen, P. L., Subramanian, T., Chinnadurai, G., Tomlinson, G., Osborne, C. K., Sharp, Z. D., and Lee, W. H. (1999) J. Biol. Chem. 274, 11334-11338[Abstract/Free Full Text]
69. Li, S., Ting, N. S., Zheng, L., Chen, P. L., Ziv, Y., Shiloh, Y., Lee, E. Y., and Lee, W. H. (2000) Nature 406, 210-215[CrossRef][Medline] [Order article via Infotrieve]
70. Iwabuchi, K., Bartel, P. L., Li, B., Marraccino, R., and Fields, S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6098-6102[Abstract]
71. Lakin, N. D., and Jackson, S. P. (1999) Oncogene 13, 7644-7655[CrossRef]
72. Burma, S., Chen, B. P., Murphy, M., Kurimasa, A., and Chen, D. J. (2001) J. Biol. Chem. 276, 42462-42467[Abstract/Free Full Text]
73. Ward, I. M., and Chen, J. (2001) J. Biol. Chem. 276, 47759-47762[Abstract/Free Full Text]
74. Celeste, A., Petersen, S., Romanienko, P. J., Fernandez-Capetillo, O., Chen, H. T., Sedelnikova, O. A., Reina-San-Martin, B., Coppola, V., Meffre, E., Difilippantonio, M. J., Redon, C., Pilch, D. R., Olaru, A., Eckhaus, M., Camerini-Otero, R. D., Tessarollo, L., Livak, F., Manova, K., Bonner, W. M., Nussenzweig, M. C., and Nussenzweig, A. (2002) Science 296, 922-928[Abstract/Free Full Text]
75. Futreal, P. A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L. M., Haugen-Strano, A., Swensen, J., Miki, Y., Eddington, K., McClure, M., Frye, C., Weaver-Feldhaus, J., Ding, W., Gholami, Z., Soderkvist, P., Terry, L., Jhanwar, S., Berchuck, A., Iglehart, J. D., Marks, J., Ballinger, D. G., Barrett, J. C., Skolnick, M. H., Kamb, A., and Wiseman, R. (1994) Science 266, 120-122[Medline] [Order article via Infotrieve]
76. Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R., Hollestelle, A., Houben, M., Crepin, E., van Veghel-Plandsoen, Elstrodt, F., van Duijn, C., Bartels, C., Meijers, C., Schutte, M., McGuffog, L., Thompson, D., Easton, D., Sodha, N., Seal, S., Barfoot, R., Mangion, J., Chang-Claude, J., Eccles, D., Eeles, R., Evans, D. G., Houlston, R., Murday, V., Narod, S., Peretz, T., Peto, J., Phelan, C., Zhang, H. X., Szabo, C., Devilee, P., Goldgar, D., Futreal, P. A., Nathanson, K. L., Weber, B., Rahman, N., and Stratton, M. R. (2002) Nat. Genet. 31, 55-59[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.